RAJAF · TFA Therapeutics, Inc.
Market Cap
$1.02B
Shares
111.12M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.25M
-0.6%
FY2025
Net Income
-$154.82K
+31.6%
FY2025
Gross Margin
61.09%
-11.2pp
FY2025
Operating Margin
-11.33%
+3.3pp
FY2025
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$35.85K
-111.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $1.25M | $1.25M | $882.53K | $53.3K | $879.32K | |
| $484.61K | $347K | $116.15K | $13.75K | $1.06M | |
| $760.74K | $906.48K | $766.39K | $39.56K | -$176.21K | |
| 61.09% | 72.32% | 86.84% | 74.21% | -20.04% | |
| — | — | — | $118.44K | $25.05K | |
| — | — | $538.55K | $336.24K | $94.34K | |
| — | — | $56.76K | $24.49K | $149.24K | |
| $901.87K | $1.09M | $538.55K | $454.68K | $119.39K | |
| -$141.13K | -$183.91K | $227.83K | -$415.12K | -$119.39K | |
| -11.33% | -14.67% | 25.82% | -778.78% | -13.58% | |
| — | — | $284.59K | -$390.63K | $29.85K | |
| — | — | $26.54K | $71.77K | $12.35K | |
| — | — | $7 | $10 | $7 | |
| -$13.69K | -$7388 | -$37.02K | $10 | $7 | |
| -$154.82K | -$191.3K | $190.82K | -$415.11K | -$119.38K | |
| — | $34.96K | $21.53K | $792 | $351 | |
| -$154.82K | -$226.26K | $751.61K | -$720.09K | -$491.01K | |
| -12.43% | -18.05% | 85.16% | -1350.92% | -55.84% | |
| -$159.01K | -$223.75K | $799.54K | -$675.52K | -$495.4K | |
| USD/shares | $0.00 | $0.00 | $0.01 | -$0.01 | -$4.91 |
| USD/shares | $0.00 | $0.00 | $0.01 | -$0.01 | -$4.91 |
| shares | 111.12M | 111.12M | 111.12M | 104.42M | 100K |
| shares | 111.12M | 111.12M | 111.12M | 104.42M | 100K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product Sales | $1,069,943 | $1,200,541 | $601,570 | — | — |
| Revenue Related Parties | $175,405 | $52,943 | $126,856 | $53,304 | — |
| Sales of Cordyceps | — | — | — | — | $879,318 |
| Training | — | — | $154,107 | — | — |